Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13677265 | 0.88 | BACE1 (0.44) | MEN1MAPTHTTKMT2APOLB | |
| SCHEMBL17876421 | 0.79 | MAPT (0.46) | MEN1MAPTKMT2APOLBPTPN1 | |
| SCHEMBL13677280 | 0.78 | ACSS2 (0.53) | MAPTHTTPTPN1 | |
| SCHEMBL8382562 | 0.78 | PTPN1 (0.42) | MEN1MAPTHTTKMT2APOLB | |
| SCHEMBL7721500 | 0.77 | POLB (0.63) | MEN1MAPTKMT2APOLB | |
| SCHEMBL13676925 | 0.75 | ACSS2 (0.42) | MEN1MAPTHTTKMT2APOLB | |
| SCHEMBL10818430 | 0.75 | RAB9A (0.46) | MEN1MAPTKMT2APTPN1 | |
| SCHEMBL29016556 | 0.74 | SMN1; SMN2 (0.43) | MEN1MAPTHTTKMT2A | |
| SCHEMBL29016636 | 0.74 | KDM4E (0.40) | MEN1MAPTHTTKMT2A | |
| SCHEMBL30370440 | 0.74 | SMN1; SMN2 (0.43) | MEN1MAPTHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264405-A1 | Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264405-A1 | Cetp Inhibitors | CETP, APOB, PCSK9 | MEN1 3792/4885MAPT 1796/4885HTT 2158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.